Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002678 | 0.81 | KCNH2 (0.43) | KDM1APOLBKCNH2GPR119CHRM4 | |
| SCHEMBL23570520 | 0.80 | POLB (0.43) | KDM1APOLBKCNH2GPR119CHRM4 | |
| SCHEMBL28611990 | 0.79 | KCNH2 (0.46) | KDM1APOLBKCNH2GPR119CHRM4 | |
| SCHEMBL30462275 | 0.79 | POLB (0.47) | POLBGPR119GRM5GRM1DTYMK | |
| SCHEMBL20732101 | 0.78 | KDM1A (0.38) | KDM1A | |
| SCHEMBL30968406 | 0.76 | KDM1A (0.39) | KDM1APOLBKCNH2GPR119CHRM4 | |
| SCHEMBL861264 | 0.74 | POLB (0.45) | POLBGPR119GRM5GRM1DTYMK | |
| SCHEMBL30454811 | 0.74 | MAPK1 (0.53) | POLBGPR119GRM5GRM1DTYMK | |
| SCHEMBL20631821 | 0.74 | POLB (0.38) | KDM1APOLBKCNH2GPR119GRM5 | |
| SCHEMBL23570688 | 0.74 | POLB (0.38) | KDM1APOLBKCNH2GPR119CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2019-10-10 | — | — | US | disclosed |
| US-6472403-B2 | IMIDAZOLIDIN-2-ONE DERIVATIVES; INHIBITING BONE RESORPTION, VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, ARTHRITIS, VIRAL DISEASE, CANCER AND METASTATIC TUMOR GROWTH | MERCK & CO., INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020037889-A1 | Alpha V integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | ITGAM, ITGB1, ITGB2 | KDM1A 2797/4885POLB 4845/4885KCNH2 2357/4885 |
| US-20020037889-A1 | Alpha V integrin receptor antagonists | ITGAV, ITGB3, ITGA5 | KDM1A 3435/4885POLB 3570/4885KCNH2 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.